Urinary Tract Infection in Children and the Potential Role of Pivmecillinam as a Treatment Option

Naja Lyhne Andersen; Valeria Antsupova; Jonas Bredtoft Boel; Mette Marie Christensen; Ulrikka Nygaard; Lisbeth Samsø Schmidt

doi:10.1097/INF.0000000000004524

Urinary Tract Infection in Children and the Potential Role of Pivmecillinam as a Treatment Option

Pediatr Infect Dis J. 2025 Jan 1;44(1):e1-e3. doi: 10.1097/INF.0000000000004524. Epub 2024 Aug 27.

Authors

Naja Lyhne Andersen^{1

2}, Valeria Antsupova³, Jonas Bredtoft Boel³, Mette Marie Christensen¹, Ulrikka Nygaard^{2

4}, Lisbeth Samsø Schmidt^{1

2}

Affiliations

¹ From the Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Herlev-Gentofte, Copenhagen, Denmark.
² Faculty of Medical and Health Sciences, University of Copenhagen, Copenhagen, Denmark.
³ Department of Clinical Microbiology, Copenhagen University Hospital Herlev-Gentofte, Copenhagen, Denmark.
⁴ Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

PMID: 39705404
DOI: 10.1097/INF.0000000000004524

Abstract

We investigated the potential role of pivmecillinam in the treatment of urinary tract infections in children. Among 351 children (0-6 years) with urinary tract infections, 83% could be treated with pivmecillinam following urine culture. Resistance was highest in infants (0-3 months) caused by the high prevalence of Enterococcus faecalis. This result emphasizes the necessity for developing a pediatric oral form of pivmecillinam.

MeSH terms

Amdinocillin Pivoxil* / therapeutic use
Anti-Bacterial Agents* / pharmacology
Anti-Bacterial Agents* / therapeutic use
Child
Child, Preschool
Drug Resistance, Bacterial
Enterococcus faecalis / drug effects
Female
Humans
Infant
Infant, Newborn
Male
Urinary Tract Infections* / drug therapy
Urinary Tract Infections* / microbiology

Substances

Anti-Bacterial Agents
Amdinocillin Pivoxil